Best Peptides for Heart and Kidney Health in 2026
A search phrased as a ranking, answered with the studies underneath it, one row per study. Each row names who was enrolled, the endpoint measured, the number with its interval, the design and the PMID. A figure belongs to the population it was measured in.
These conditions are managed with a doctor
Heart failure, hypertension, hepatorenal syndrome and chronic kidney disease are diagnosed and treated by physicians. The human trials below ran under investigators, with participants selected against written entry criteria. This page reports what each study measured and in whom, and tells nobody what to take. Our therapeutic peptides overview covers how prescription and research-market supply sit side by side in Vietnam.
17,604
Enrolled in SELECT (PMID 37952131)
3,533
Randomised in FLOW (PMID 38785209)
2
Adults in the 2025 BPC-157 pilot (PMID 40131143)
The Studies
A compound studied more than once gets a row for each study. Read each row against the population beside it.
| Compound | Population (n) | What was measured | Result | Design | PMID |
|---|---|---|---|---|---|
| Semaglutide | 17,604 adults 45+, preexisting cardiovascular disease, BMI 27+, no diabetes | Cardiovascular death, non-fatal myocardial infarction or non-fatal stroke | 6.5% vs 8.0%; HR 0.80 (0.72 to 0.90), P<0.001; mean 39.8 months | Randomised double-blind placebo-controlled (SELECT) | 37952131 |
| Semaglutide | 3,533 adults, type 2 diabetes plus chronic kidney disease | Major kidney disease events: kidney failure, 50%+ eGFR fall, kidney or cardiovascular death | 331 vs 410 events; HR 0.76 (0.66 to 0.88), P=0.0003; all-cause death HR 0.80 (0.67 to 0.95) | Randomised placebo-controlled, stopped early at interim (FLOW) | 38785209 |
| Liraglutide | 9,340 adults, type 2 diabetes, high cardiovascular risk | Composite renal outcome: macroalbuminuria, doubled creatinine, end-stage renal disease | 268/4,668 vs 337/4,672; HR 0.78 (0.67 to 0.92), P=0.003 | Prespecified secondary renal analysis (LEADER) | 28854085 |
| Tirzepatide | 731 patients, heart failure, ejection fraction 50%+, BMI 30+ | Cardiovascular death or worsening heart failure event | 9.9% vs 15.3%; HR 0.62 (0.41 to 0.95), P=0.026. Cardiovascular deaths alone 8 vs 5, HR 1.58 (0.52 to 4.83) | Randomised double-blind placebo-controlled (SUMMIT) | 39555826 |
| Sacubitril with valsartan, blocking the enzyme that degrades natriuretic peptides | 8,442 patients, ejection fraction 40% or less | Cardiovascular death or heart failure hospitalisation | 21.8% vs 26.5% on enalapril; HR 0.80 (0.73 to 0.87), P<0.001; stopped early | Randomised double-blind, enalapril comparator (PARADIGM-HF) | 25176015 |
| Sacubitril with valsartan | 4,822 patients, ejection fraction 45%+, raised natriuretic peptides | Total heart failure hospitalisations plus cardiovascular death | 894 vs 1,009 events; rate ratio 0.87 (0.75 to 1.01), P=0.06 | Randomised, valsartan comparator (PARAGON-HF) | 31475794 |
| Nesiritide, a recombinant B-type natriuretic peptide | 7,141 patients hospitalised with acute heart failure | Rehospitalisation or death within 30 days; dyspnoea at 6 hours | 9.4% vs 10.1%, P=0.31; dyspnoea 44.5% vs 42.1%, under the prespecified threshold | Randomised placebo-controlled infusion (ASCEND-HF) | 21732835 |
| Ularitide, a synthetic natriuretic peptide | 2,157 patients with acute heart failure | Cardiovascular death over a median 15 months | 21.7% vs 21.0%; HR 1.03 (96% CI 0.85 to 1.25), P=0.75 | Randomised double-blind placebo-controlled, 48 hour infusion (TRUE-AHF) | 28402745 |
| Angiotensin II | 321 patients in vasodilatory shock, already on high-dose vasopressors | Mean arterial pressure response at hour 3 | 69.9% vs 23.4%; odds ratio 7.95 (4.76 to 13.3), P<0.001. Day 28 death 46% vs 54%, HR 0.78 | Randomised placebo-controlled, intensive care (ATHOS-3) | 28528561 |
| Etelcalcetide | 1,023 haemodialysis patients, moderate to severe secondary hyperparathyroidism | Fall over 30% in mean parathyroid hormone, weeks 20 to 27 | Trial A 74.0% vs 8.3%; trial B 75.3% vs 9.6%; both P<0.001. Authors say clinical outcomes need further study | Two parallel phase 3 randomised placebo-controlled trials | 28097355 |
| Difelikefalin | 378 haemodialysis patients with moderate to severe itch | Fall of at least 3 points at week 12, Worst Itching Intensity scale | Imputed 49.1% vs 27.9%, P<0.001. Diarrhoea, dizziness and vomiting more common on the drug | Randomised double-blind placebo-controlled phase 3 (KALM-1) | 31702883 |
| Terlipressin with albumin | 300 adults, cirrhosis with type 1 hepatorenal syndrome | Verified reversal on serum creatinine, 10 days without dialysis | 32% vs 17%, P=0.006. Day 90 death from respiratory disorders 11% vs 2%; all-cause 51% vs 45% | Randomised placebo-controlled phase 3 (CONFIRM) | 33657294 |
| NT-proBNP, measured rather than administered | 1,461 breathless emergency patients; 277 adjudicated acute heart failure | Diagnostic accuracy at age-stratified cutpoints and a 300 pg/ml rule-out | ROC area 0.91 (0.90 to 0.93). Below 300 pg/ml: sensitivity 93.9%, negative predictive value 98.0% | Prospective diagnostic accuracy study (ICON-RELOADED) | 29544601 |
| Lactotripeptides IPP and VPP, from milk protein | 1,306 European participants, 14 trials | Systolic and diastolic blood pressure | Systolic 1.28 mm Hg lower (0.48 to 2.09 lower), P=0.0017; diastolic 0.59 mm Hg lower | Random-effects meta-analysis of randomised trials | 23382495 |
| Semaglutide and tirzepatide, in hypertension | Adults with hypertension: a semaglutide trial (274) and a tirzepatide trial (153 with stage 2 hypertension), inside 8 trials | Mortality, cardiovascular morbidity, serious adverse events, adverse events | The review states no results were reported for either drug on those outcomes, and concludes the evidence in hypertension remains insufficient for conclusions about mortality or morbidity | Cochrane systematic review, searched to 22 April 2024 | 42318855 |
| Thymosin beta 4, synthetic | 40 healthy volunteers, four cohorts of 10 | Adverse events, dose limiting toxicity, pharmacokinetics | Adverse events infrequent, mild or moderate; no dose limiting toxicities or serious adverse events | Randomised placebo-controlled ascending dose study | 20536472 |
| Thymosin beta 4 pre-treating endothelial progenitor cells | 10 patients with ST elevation myocardial infarction, five per arm | Six-minute walking distance at 6 months | Rose 75.7 m vs 38.2 m with untreated cells; difference 37.5 m (28.7 to 56.3), P<0.01 | Randomised pilot, untreated cells as comparator | 27288307 |
| BPC-157 | 2 adults at a private Florida clinic | Biomarkers of heart, liver, kidneys, thyroid and glucose over three days | No measurable effects on the tested biomarkers; tolerated, no side effects reported. Authors call for further safety study | Open-label pilot, two intravenous infusions | 40131143 |
| BPC-157 | Rat preparations in a 2022 narrative review: vessel occlusion, deep vein thrombosis, arrhythmia, infarction | Vessel patency, collateral recruitment, thrombocyte counts, organ lesions | The review reports counteracted thrombosis and thrombocytopenia, coagulation pathways unaffected, collateral vessels recruited | Narrative review of animal experiments, no human arm | 36359218 |
Doses as the Protocols Set Them
Amounts assigned by the published protocols of studies in the table:
SELECT: semaglutide 2.4 mg once weekly, subcutaneous, or placebo (PMID 37952131).
FLOW: semaglutide 1.0 mg once weekly, subcutaneous, or placebo (PMID 38785209).
SUMMIT: tirzepatide up to 15 mg subcutaneously once weekly, or placebo (PMID 39555826).
2025 pilot report: BPC-157 10 mg intravenously on day 1, then 20 mg on day 2, in two adults (PMID 40131143).
Disclaimer: these figures are what published protocols assigned to enrolled participants under investigator supervision. They are facts about those studies, not a recommendation, a starting point or a titration schedule. With impaired kidney function, an amount is set by a treating clinician rather than copied from a paper.
Kidney Function
Searches phrased as best peptide for kidney function land on FLOW, so it is worth knowing what FLOW was built to do. FLOW set major kidney disease events as its primary outcome and entered participants on eGFR and albumin-to-creatinine bands (PMID 38785209). LEADER ran as a cardiovascular trial and reported its renal composite as a prespecified secondary analysis (PMID 28854085). Background sits on the semaglutide profile and the side effect guide.
Kidney patients were enrolled for other endpoints too. Etelcalcetide was measured on parathyroid hormone concentration in haemodialysis patients with moderate to severe secondary hyperparathyroidism (PMID 28097355). Difelikefalin was measured on an itch score in haemodialysis patients (PMID 31702883). Terlipressin with albumin was measured on reversal of hepatorenal syndrome in adults with cirrhosis (PMID 33657294). Each of those endpoints answers its own question, and a reader looking for filtration should check which endpoint a figure came from.
Blood Pressure
Searches phrased as best peptide for high blood pressure meet a literature that moves in both directions. ATHOS-3 studied a peptide that raises pressure, in patients already in vasodilatory shock, an intensive care setting rather than a hypertension one (PMID 28528561). A pooled lowering figure comes from milk-derived tripeptides eaten rather than injected (PMID 23382495). Hypertension is diagnosed and treated by a doctor.
Natriuretic Peptides, Given and Measured
The heart makes its own peptides, and studies have gone at them from different directions. ASCEND-HF and TRUE-AHF infused synthetic versions and reported their coprimary endpoints unmet (PMID 21732835, PMID 28402745). PARADIGM-HF and PARAGON-HF blocked the enzyme that degrades them, at different ejection fraction bands and against different comparators (PMID 25176015, PMID 31475794). ICON-RELOADED measured NT-proBNP in blood rather than giving it, so its figures are concentrations and diagnostic cutpoints rather than amounts (PMID 29544601). Our bloodwork guide for Vietnam covers where panels are run.
Research-Market Compounds
BPC-157 and thymosin beta 4 are sold into this question, and the studies behind those names differ in what they enrolled. A 2022 narrative review collected rat preparations (PMID 36359218). A 2025 open-label pilot infused two adults at a private Florida clinic (PMID 40131143). An ascending dose study gave synthetic thymosin beta 4 intravenously to healthy volunteers (PMID 20536472), and a randomised pilot pre-treated transplanted cells with it in patients after myocardial infarction (PMID 27288307). Each study supports a claim the size of itself: a six-minute walking distance measured in ten patients is a result in those ten patients. Our BPC-157 profile and compounds discussed for longevity go further into each.
Reading This in Vietnam
A 2026 meta-analysis pooled 42 studies covering 2,271,169 participants across Asia and reported chronic kidney disease prevalence of 17.0 percent for stages 1 to 5 and 7.7 percent for stages 3 to 5 (PMID 41797416). The practical reading is to measure rather than infer. Product identity is a further local problem, since a mislabelled vial matters more when clearance is impaired: see fake GLP-1 products, reading a Certificate of Analysis and the GLP-1 access guide.
Questions worth taking into a consultation:
- What is my eGFR and albumin-to-creatinine ratio, and what were they twelve months ago?
- Does my situation resemble the population enrolled in the trial being quoted at me?
- Which of my current medicines interact with anything proposed?
Search Provenance
Facts about searches, not about the world. A query matches the words and index tags a record carries, so a synonym can sit outside a compound-name search.
- ("BPC 157"[tiab] OR "BPC-157"[tiab] OR "pentadecapeptide BPC 157"[tiab]) AND ("heart"[tiab] OR "cardiac"[tiab] OR "myocardial"[tiab] OR "kidney"[tiab] OR "renal"[tiab]) in PubMed on 9 August 2026 returned 34 records.
- ("BPC 157"[tiab] OR "BPC-157"[tiab] OR "pentadecapeptide BPC 157"[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt]) in PubMed on 9 August 2026 returned 0 records.
- ("thymosin beta 4"[tiab] OR "thymosin beta-4"[tiab] OR "TB-500"[tiab] OR "thymosin beta4"[MeSH Terms]) AND ("myocardial infarction"[tiab] OR "heart failure"[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt]) in PubMed on 9 August 2026 returned 1 record, PMID 20536472.
Frequently Asked Questions
I searched for best peptides for heart health and got a ranking. What sits under it?+
Individual studies, each with its own entry criteria. Some are medicines tested in randomised trials that enrolled adults who already carried a cardiovascular diagnosis (PMID 37952131). Some are pilot reports run at a single private clinic (PMID 40131143). A ranked answer drops the entry criteria, so it stops saying who a figure describes. Read the population column beside any number before treating it as a number about you. These conditions are managed with a doctor.
Does a result found in people with type 2 diabetes apply to kidney disease without diabetes?+
FLOW and LEADER both enrolled diabetic populations. FLOW randomised participants who had type 2 diabetes and chronic kidney disease together, entered on eGFR and albumin-to-creatinine bands (PMID 38785209). LEADER reported prespecified secondary renal outcomes in participants with type 2 diabetes and high cardiovascular risk (PMID 28854085). Extending either past that population is a step neither trial was designed to support, and a clinician reading your own eGFR and albumin-to-creatinine ratio can judge that better than a page.
Why did the same mechanism succeed in one heart failure trial and miss in another?+
Because PARADIGM-HF and PARAGON-HF enrolled different patients and used different comparators. PARADIGM-HF entered patients at the reduced ejection fraction band and randomised them against enalapril (PMID 25176015). PARAGON-HF entered patients at the preserved band and randomised them against valsartan (PMID 31475794). Same enzyme target, different entry band, different comparator, different verdict.
Does reduced kidney function change how any of this behaves in the body?+
That is a question for the prescriber managing the kidney. FLOW set entry bands on eGFR and albumin-to-creatinine ratio rather than enrolling anyone simply described as having kidney disease, so degree of function is treated as something that changes the answer (PMID 38785209). CONFIRM enrolled adults whose kidneys were failing because of cirrhosis, and reported harms alongside its renal endpoint, including deaths from respiratory disorders by day 90 in each arm (PMID 33657294). Bring recent eGFR and albumin-to-creatinine numbers to the consultation, and the same numbers from twelve months ago if you have them.
What can a study in healthy volunteers tell someone who already has a diagnosis?+
It reports what the protocol measured, in the people enrolled, at the exposures tested. The intravenous thymosin beta 4 study measured adverse events and pharmacokinetics in healthy volunteers across ascending doses, which is a tolerability question (PMID 20536472). The intravenous BPC-157 pilot measured blood biomarkers over three days in the adults it infused (PMID 40131143). A tolerability measurement made in people without the condition stays a measurement in people without the condition, whatever the compound is later sold for.
What is worth bringing to a consultation about this in Vietnam?+
Product identity, alongside your numbers. Prescription supply and research-market supply sit side by side here, and a published study used a defined product at a defined amount under investigator supervision, so the consultation has to start from what is actually in the vial in front of you. Bring the packaging, the batch number and whatever certificate of analysis came with it, and bring the PMID of any study being quoted at you so its population can be read next to yours. A doctor can then judge whether any of it applies to you.
Reminder: this page is education, not medical advice, and not a protocol. Each figure was read from the record of the study named beside it, through NCBI E-utilities, while the page was written. Amounts appear as descriptions of published trial protocols. If you hold a cardiac or renal diagnosis, take this page to your doctor.